Skip to main content

Table 2 Clinical characteristics and HAE therapy history of case series patients

From: Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada

Case

Type of attacks

Most debilitating attacks

Pre-lana LTP

Pre-lana acute treatment

Lana transition date

Lana dosage

Post-lana acute treatment

1

Extremity swelling

Abdominal pain

Laryngeal swelling

Laryngeal swelling

C1-INH 2000U IV q3-4d

Icatibant 30 mg SC

January 2020

300 mg SC q2w

Icatibant 30 mg SC

2

Abdominal pain

Lip swelling

Abdominal pain

C1-INH 3000U IV q3d

C1-INH 3000U IV

July 2019

300 mg SC q2w

C1-INH 3000U IV

3

Extremity swelling

Laryngeal swelling

Laryngeal swelling

C1-INH 1500U IV q5d

Icatibant 30 mg SC

January 2020

300 mg SC q2w

Icatibant 30 mg SC

4

Extremity swelling

Abdominal pain

Abdominal pain

C1-INH 1500U IV q3-4d

Icatibant 30 mg SC

October 2019

300 mg SC q4w

Icatibant 30 mg SC

5

Extremity swelling

Abdominal pain

Lip swelling

Headaches

Abdominal pain

C1-INH 1500U IV q3-4d

C1-INH 3000U IV

April 2020

300 mg SC q2w

C1-INH 1500U IV

6

Abdominal pain

Extremity swelling

Laryngeal swelling

Abdominal pain

C1-INH 1500U IV q3d

Icatibant 30 mg SC

April 2019

300 mg SC q2w

Icatibant 30 mg SC

7

Abdominal pain

Extremity swelling

Laryngeal swelling

Abdominal pain

None

None

October 2020

300 mg SC q2w

Icatibant 30 mg SC

8

Abdominal pain

Extremity swelling

Abdominal pain

C1-INH 4500U SC q3-4d

Icatibant 30 mg SC

February 2020

300 mg SC q2w

Icatibant 30 mg SC

9

Extremity swelling

Extremity swelling

None

Prednisonea

February 2020

300 mg SC q2w

Icatibant 30 mg SC

10

Abdominal pain

Extremity swelling

Laryngeal swelling

Abdominal attacks

Danazol C1-INH 4500U SC q3-4d

C1-INH IV

May 2019

300 mg SC q2w

C1-INH IV

11

Lip swelling

Abdominal pain

Laryngeal swelling

Laryngeal swelling

TXA C1-INH 1500U IV q2-3d

Icatibant or C1-INH IV

January 2020

300 mg SC q2w

Icatibant or C1-INH IV

12

Abdominal pain

Laryngeal swelling

Abdominal, Laryngeal

Danazol C1-INH 2000U IV q3-4d

Icatibant or C1-INH IV

October 2020

300 mg SC q2w

Icatibant

  1. All data was extracted from patient chart review
  2. LTP long-term prophylaxis, C1-INH plasma-derived C1 esterase inhibitor enzyme, TXA tranexamic acid
  3. aPrednisone was given to this patient as acute treatment prior to HAE diagnosis and was ineffective at treating attacks